The first in a new class of gene-silencing drugs, known as inclisiran, has been shown to halve cholesterol levels in patients at risk of cardiovascular disease.
The first in a new class of gene-silencing drugs, known as inclisiran, has been shown to halve cholesterol levels in patients at risk of cardiovascular disease.